Clinical trial
Study of Tarceva and Targretin in Stage I-II Lung Cancer
NCT00125372 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00125372 |
|---|---|
| Title | Study of Tarceva and Targretin in Stage I-II Lung Cancer |
| Official title | A Clinical and Pharmacologic Study of the Combination of Erlotinib and Bexarotene in Resectable Clinical Stage I-II Non-Small Cell Lung Cancer |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | Ligand Pharmaceuticals Industry Genentech, Inc. |
| Status | Completed |
| Study type | Interventional |
| Conditions | Carcinoma, Non-small-cell Lung |
| Intervention type | Drug |
| Interventions | erlotinib (Tarceva) and bexarotene (Targretin) |
| Enrollment | 12 |
| Start date | Dec 1, 2005 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Aug 1, 2005 |
| Last update posted | Jan 8, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: